Get the Stockscreener App
8.70
0.35%
0.03
Intellia Therapeutics Inc stock is traded at $8.70, with a volume of 6.85M.
It is up +0.35% in the last 24 hours and down -63.60% over the past month.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$8.67
Open:
$8.49
24h Volume:
6.85M
Relative Volume:
0.89
Market Cap:
$933.92M
Revenue:
$52.86M
Net Income/Loss:
$-480.19M
P/E Ratio:
-1.8551
EPS:
-4.6899
Net Cash Flow:
$-421.82M
1W Performance:
-8.61%
1M Performance:
-63.60%
6M Performance:
+10.41%
1Y Performance:
-42.46%
1-Day Range:
$8.38
$8.88
1-Week Range:
$8.38
$10.77
52-Week Range:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
8.70 | 1.00B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-11-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-28-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-27-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-27-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Can volume confirm reversal in Intellia Therapeutics Inc.July 2025 News Drivers & Reliable Volume Spike Alerts - newser.com
Why Intellia Therapeutics Inc. (38I) stock remains top ratedQuarterly Trade Summary & Fast Entry Momentum Trade Alerts - newser.com
How Intellia Therapeutics Inc. stock performs in weak economyJuly 2025 EndofMonth & Real-Time Volume Triggers - newser.com
2 Beaten-Down Stocks to Avoid Right Now - AOL.com
Will Intellia Therapeutics Inc. (38I) stock outperform value peersRecession Risk & Daily Profit Maximizing Tips - newser.com
Will Intellia Therapeutics Inc. (38I) stock recover faster than industry2025 Breakouts & Breakdowns & Free Expert Verified Stock Movement Alerts - newser.com
What data driven models say about Intellia Therapeutics Inc.’s futureEarnings Recap Report & Verified Chart Pattern Signals - newser.com
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? - Yahoo Finance
Will Intellia Therapeutics Inc. (38I) stock benefit from mergersMarket Activity Recap & Free Daily Entry Point Trade Alerts - newser.com
Intellia Therapeutics Reports Q3 2025 Financial Results - TipRanks
Can Intellia Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Fed Impact & Scalable Portfolio Growth Methods - newser.com
Korro to cut staff, shift strategy as RNA editing drug misses mark in early testing - BioPharma Dive
Should You Buy the Dip in Intellia Therapeutics Stock? - Barchart.com
Intellia Therapeutics Stock Hits Day Low of $8.96 Amid Price Pressure - Markets Mojo
Can technical indicators confirm Intellia Therapeutics Inc.’s reversal2025 Volatility Report & Reliable Trade Execution Plans - newser.com
Intellia Therapeutics, Inc.Common Stock (NQ: NTLA - FinancialContent
Intellia Therapeutics (NTLA) Downgraded Amid Safety Concerns - GuruFocus
Intellia cut to Peer Perform at Wolfe Research on Nex-z safety issues - Seeking Alpha
JonesTrading downgrades Intellia Therapeutics (NTLA) to a Hold - The Globe and Mail
NTLA Sees Another Downgrade as Wolfe Research Adjusts Rating | N - GuruFocus
Intellia Therapeutics (NTLA) Downgraded by Wolfe Research Due to Safety Concerns - GuruFocus
Is Intellia Therapeutics Inc. (38I) stock trading at attractive multiples2025 Historical Comparison & Risk Adjusted Buy and Sell Alerts - newser.com
Intellia Reports Favorable Phase 1 Data for Nex-Z - MSN
Is a relief rally coming for Intellia Therapeutics Inc. holders2025 Bull vs Bear & AI Forecasted Stock Moves - newser.com
Intellia Therapeutics (NTLA) Downgraded to 'Hold' by Jones Tradi - GuruFocus
Intellia Therapeutics (NTLA): Assessing Valuation After FDA Clinical Hold on Lead Gene-Editing Program - Yahoo Finance
Is Intellia Therapeutics Inc 38I a good long term investmentStraddle and Strangle Trades & Take Advantage of Momentum Stocks - earlytimes.in
What analysts say about Intellia Therapeutics Inc 38I stockGlobal Trade Effects & Superior Growth Trading - earlytimes.in
Jones Downgrades Intellia Therapeutics to Neutral From Buy - MarketScreener
Is This Beaten-Down Cathie Wood Stock Still a Buy? - Yahoo Finance
Evercore ISI Downgrades Intellia Therapeutics to In Line From Outperform, Adjusts PT to $8 From $17 - MarketScreener
This SPS Commerce Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
What 21 Analyst Ratings Have To Say About Intellia Therapeutics - Benzinga
How sentiment analysis helps forecast Intellia Therapeutics Inc.Quarterly Market Review & Daily Profit Maximizing Trade Tips - newser.com
Evercore ISI Group Downgrades NTLA with Significant Price Target Cut | NTLA Stock News - GuruFocus
Intellia Therapeutics Faces Critical Regulatory Hurdle Despite Promising Trial Data - AD HOC NEWS
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):